Accordingly, failure to maintain these metabolites in balance was associated with several age-associated conditions including cancer and Alzheimer’s disease, making ASAH1 an attractive therapeutic target [25, 51, 52]. Here, ASAH1 is linked to early-onset autosomal dominant Alzheimer disease.